Chemo-radiation with or without mandatory split in anal carcinoma: Experiences of two institutions and review of the literature

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Oehler, Christoph ^a   Provencher, Sawyna ^b   Donath, David ^c   Bahary, Jean Paul ^c   Lütolf, Urs M ^a   Ciernik, I Frank ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c NOTRE DAME HOSPITAL   (Canada)

^d DESSAU MEDICAL CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN C; ANTINEOPLASTIC AGENT; MITOMYCIN;

ADULT; ANUS CANCER; ANUS CARCINOMA; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANADA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; DERMATITIS; DIARRHEA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FISTULA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART FAILURE; HERPES VIRUS INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROCTITIS; RADIATION DOSE; SKIN ULCER; TREATMENT DURATION; TREATMENT RESPONSE; URINE INCONTINENCE; ANUS TUMOR; COMPUTER ASSISTED RADIOTHERAPY; LITERATURE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION RESPONSE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; REVIEW LITERATURE AS TOPIC; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952065244     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-36     Document Type: Article

References (34)

1. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. Jama 2008, 299:1914-1921. 10.1001/jama.299.16.1914, 18430910.
2. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996, 14:2527-2539.
3. Epidermoidanal cancer results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996, 348:1049-1054. 10.1016/S0140-6736(96)03409-5, 8874455, Epidermoidanal cancer.
4. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15:2040-2049.
5. Cummings BJ, Keane TJ, O'Sullivan B, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991, 21:1115-1125.
6. John M, Pajak T, Flam M, et al. Dose Escalation in Chemoradiation for Anal Cancer: Preliminary Results of RTOG 92-08. Cancer J Sci Am 1996, 2:205.
7. Bosset JF, Roelofsen F, Morgan DA, et al. Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 2003, 39:45-51. 10.1016/S0959-8049(02)00377-5, 12504657.
8. Konski A, Garcia M, John M, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008, 72:114-118. 2570743, 18472363.
9. Vuong T, Devic S, Belliveau P, et al. Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. Int J Radiat Oncol Biol Phys 2003, 56:823-831.
10. Vuong T, Kopek N, Ducruet T, et al. Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67:1394-1400.
11. Meyer A, Meier Zu Eissen J, Karstens JH, Bremer M. Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome. Acta Oncol 2006, 45:728-735. 10.1080/02841860600726729, 16938816.
12. Oehler-Janne C, Seifert B, Lutolf UM, et al. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy 2007, 6:218-226. 10.1016/j.brachy.2007.02.152, 17681244.
13. Huang EY, Wang CJ, Chen HC, et al. Multivariate analysis of pulmonary fibrosis after electron beam irradiation for postmastectomy chest wall and regional lymphatics: evidence for non-dosimetric factors. Radiother Oncol 2000, 57:91-96. 10.1016/S0167-8140(00)00211-5, 11033193.
14. Allal AS, Mermillod B, Roth AD, et al. The impact of treatment factors on local control in T2-T3 anal carcinomas treated by radiotherapy with or without chemotherapy. Cancer 1997, 79:2329-2335. 10.1002/(SICI)1097-0142(19970615)79:12<2329::AID-CNCR6>3.0.CO;2-G, 9191520.
15. Weber DC, Kurtz JM, Allal AS. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2001, 50:675-680.
16. Graf R, Wust P, Hildebrandt B, et al. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 2003, 65:14-22. 10.1159/000071200, 12837978.
17. Constantinou EC, Daly W, Fung CY, et al. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 1997, 39:651-657.
18. Widder J, Kastenberger R, Fercher E, et al. Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol 2008, 87:367-375. 10.1016/j.radonc.2008.05.001, 18501453.
19. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, et al. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys 2005, 61:1136-1142.
20. Schneider IH, Grabenbauer GG, Reck T, et al. Combined radiation and chemotherapy for epidermoid carcinoma of the anal canal. Int J Colorectal Dis 1992, 7:192-196. 10.1007/BF00341219, 1293239.
21. Conroy T, Ducreux M, Lemanski C, et al. Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial. J Clin Oncol 2009, 27. abstr 4033.
22. Vuong T, Faria S, Ducruet T, et al. Changes in treatment toxicity pattern using the combined treatment of patients with anal canal cancer and early local recurrence results associated with the introduction of new radiation technologies: 3D conformal therapy and intensity modulated radiation therapy. 2008, ASCO Meeting, Edition, Abstract #4608.
23. Doci R, Zucali R, Bombelli L, et al. Combined chemoradiation therapy for anal cancer. A report of 56 cases. Ann Surg 1992, 215:150-156. 10.1097/00000658-199202000-00010, 1242403, 1546901.
24. Mai SK, Welzel G, Hermann B, et al. Long-term outcome after combined radiochemotherapy for anal cancer - retrospective analysis of efficacy, prognostic factors, and toxicity. Onkologie 2008, 31:251-257. 10.1159/000121362, 18497514.
25. Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 2007, 68:794-800.
26. Tanum G, Tveit K, Karlsen KO, Hauer-Jensen M. Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity. Cancer 1991, 67:2462-2466. 10.1002/1097-0142(19910515)67:10<2462::AID-CNCR2820671012>3.0.CO;2-1, 2015547.
27. Gerard JP, Chapet O, Samiei F, et al. Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. Cancer 2001, 92:77-84. 10.1002/1097-0142(20010701)92:1<77::AID-CNCR1294>3.0.CO;2-P, 11443612.
28. Nguyen BT, Joon DL, Khoo V, et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol 2008, 87:376-382. 10.1016/j.radonc.2008.04.003, 18453023.
29. Gretschel S, Warnick P, Bembenek A, et al. Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal. Eur J Surg Oncol 2008, 34:890-894.
30. Sischy B, Doggett RL, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst 1989, 81:850-856. 10.1093/jnci/81.11.850, 2724350.
31. Ceresoli GL, Ferreri AJ, Cordio S, Villa E. Role of dose intensity in conservative treatment of anal canal carcinoma. Report of 35 cases. Oncology 1998, 55:525-532. 10.1159/000011907, 9778618.
32. Grabenbauer GG, Kessler H, Matzel KE, et al. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum 2005, 48:1742-1751. 10.1007/s10350-005-0098-5, 15991058.
33. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007, 25:4581-4586. 10.1200/JCO.2007.12.0170, 17925552.
34. Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005, 63:354-361.